Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146528 | 0.87 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29823214 | 0.84 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1147208 | 0.84 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3256021 | 0.84 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17420534 | 0.84 | CES2 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30628232 | 0.84 | CES2 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL603415 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3258137 | 0.83 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22950515 | 0.81 | DGAT1 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12780972 | 0.81 | CA12 (0.57) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704096-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025076017-A1 | CARBAMATES FOR USE AS SARM1 INHIBITORS | GENENTECH, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-112204012-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023045960-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | 四川汇宇制药股份有限公司 | 2023-03-30 | — | — | WO | disclosed |
| US-20210205277-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-07-08 | — | — | US | disclosed |
| CN-112204012-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-3704096-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| WO-2011073160-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-5886210-A | Method for preparing aromatic compounds | ROHM AND HAAS COMPANY (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0825173-A1 | Method for preparing aromatic compounds | ROHM AND HAAS COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | SLC6A3, OPRL1, OPRK1 | CA12 4847/4885CA1 4792/4885CA2 3689/4885 |
| US-20210205277-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | CA12 4858/4885CA1 4872/4885CA2 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.